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Abstract
Stem cells seem to offer an alternative venue for treating many cell related diseases, such as age-related macular degeneration 
(ARMD) . ARMD is a progressive neurodegenerative medical condition, which primarily affects the retinal pigmented epithelium 
(RPE), resulting in degeneration of photoreceptors . Scientists have been successful in implanting stem cells into the eyes of rats . 
These injected cells sustained visual function and photoreceptor integrity without any cancerous cell formation . There are numer-
ous treatments available to slow down the progression of ARMD . Depending on the type of ARMD, doctors may either recommend 
leading a healthier lifestyle or that one should undergo surgery . Numerous risk factors can increase one’s chances of getting 
ARMD depending on one’s age and race . Bad habits, such as cigarette smoking, can contribute to the progression of ARMD . It 
is important to get a comprehensive dilated eye exam periodically . Many eye diseases that don’t have any warning signs can be 
detected with such an eye exam .




The most versatile cell types in the human body are embryonic 
stem cells. Stem cells have three unique general properties that 
distinguish them from other cells in the body. One is that these 
cells can replicate themselves even after long periods of inac-
tivity. Secondly, stem cells are unspecialized. These cells are not 
programed to become any specific tissue. For example, stem 
cells can’t work with other red blood cells to carry oxygen 
containing molecules through the blood stream. Thirdly, under 
certain physiologic or experimental conditions, stem cells can 
become the specialized cells that make up tissues and organs 
(National Institutes of Health 2016).
When stem cells divide, they can make either more stem cells, 
or can differentiate into a specialized cell which is tasked with 
a specific function. For example, these stem cells can turn into 
motoneurons which are used for motor skill or into cardio-
myocytes to help pump blood through the arteries. However, 
Adult stem cells can only generate cells that are like the tissue 
in which they are located in (Tuch, 2006). For example, hemato-
poietic stem cells in the bone marrow form only cells that give 
rise to the different types of blood cells and cannot make nerve 
cells for the brain. 
Embryonic stem cells are made from oocytes that have been 
fertilized in vitro and not in a women’s body. The process of 
priming the cells in an in vitro fertilization clinic is known as cell 
culture. Human embryonic stem cells are primed by placing an 
embryo into a culture dish that contains a culture medium. With 
the right physiological conditions, these cells begin to divide 
and spread over the surface of the dish forming millions of un-
specialized stem cells. Although scientists have not agreed upon 
a battery of tests to ensure they are growing only unspecialized 
cells, there are some common tests performed to determine 
the cells fundamental properties. One technique used is by 
looking for particular cell surface markers, such as transcription 
factors, that are generally produced by undifferentiated cells.
Stem cells in their culture dish can remain undifferentiated 
as long as they are under the appropriate conditions. However, 
cells automatically begin to differentiate once they are allowed 
to cluster together to form embryoid bodies. These cells can 
then begin to form tissue specific cells, such as muscle or nerve 
cells. Although differentiation is a sign of a healthy culture, this 
process is generally uncontrolled, and therefore an inefficient 
way to produce specialized cells. In order to create a more con-
trolled experiment, scientists change around the chemical com-
position of the culture medium or by inserting specific genes to 
specialize the cells in an organized fashion.
Human embryonic stem cells have many applications in clin-
ical use and in research. One useful application is in cell-based 
therapies, situations where stem cells are induced to turn into 
specialized cells. Through this process, new cells which are 
needed to repair destroyed tissue can be formed. For exam-
ple, these specialized cells can replace bone marrow, muscle, 
and brain cells that are injured or malfunctioning. These cells 
form an internal repair system by cell mitosis for as long as the 
organism is alive. Due to their ability to replace damaged cells, 
stem cells seem to offer an alternative venue for treating many 
cell related diseases as well. If scientists can reliably find a way 
to differentiate the cells in an organized manner, then they may 
be able to cure many diseases in the future (Weiss, Troyer, 2006).
One of the diseases that scientists believe embryonic stem 
cells can treat is age related macular degeneration (ARMD) 
(Shroff, 2015). Over 10 million Americans have vision loss re-
lated to Macular degeneration. Macular degeneration is the 
third most common pathological condition leading to vision 
impairment (Resnikoff, et. al., 2004). ARMD is a progressive neu-
rodegenerative medical condition, which primarily affects the 
retinal pigmented epithelium (RPE), resulting in degeneration 
of photoreceptors. This causes loss of vision in the center of 
the field of vision. The disease is caused by the deterioration of 
the macula, a region that is located at the center of the retina 
and is responsible for focusing central vision in the eye. This 
allows people to ride their bike or recognize a familiar face. 
Common symptoms include not being able to see in dim light, 
seeing spots, and distorted vision. 
There are two types of ARMD. There is the wet as well as 
the dry form. Most of the cases of ARMD are the dry form. 
Dry ARMD is also known as non-neovascular ARMD as well 
as non-exudative ARMD since there areno fluids that leak into 
the macula from blood vessels. Although people with this form 
of ARMD may have fair central vision of at least 20/40, they 
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may have other functional limitations, such as fluctuating vision, 
poor night vision, and pixelated vision. In this form of ARMD, 
the deterioration by the macula is linked with the appearance 
of drusen. Drusen are small yellow deposits that form under 
the macula. These deposits are buildups of shapeless acellular 
debris from the basement membrane of the RPE. This buildup 
of drusen causes the macula to thin and dry out, thereby causing 
the macula to lose its function. This process is known as atrophy. 
The amount of vision loss that occurs is directly proportional 
to the amount as well as the location of the drusen. Advanced 
cases of dry ARMD are also known as geographic atrophy (GA) 
since large areas of the retina stop functioning. Patients with GA 
usually see large blank spots in their central vision because their 
macula has deteriorated. Usually, most people over 50 years old 
have a drusen buildup in at least one of their eyes. Currently, 
there is no known cure for this form of the disease.
However, some cases of dry ARMD progress into the wet 
form. In the wet form, there is an abnormal blood vessel growth 
under the macula. This type of growth is known as choroidal 
neovascularization (CNV). Once CNV has occurred in one eye, 
the patient has a higher risk that the other eye will get CNV 
as well. These new blood vessels are generally weak and can 
rupture easily. When they rupture, they leak fluids, such as blood 
and lipid containing solutions. This causes the macula to bulge, 
thereby causing a distorted central vision. These conditions can 
cause severe vision loss in a short amount of time. In this form 
of ARMD, patients may see spots because of the fluid buildup 
under the macula. Therefore, periodic eye exams are vital, es-
pecially if the patient is at a higher risk of contracting ARMD.
There are three stages in ARMD. There is early, intermediate, 
and late stage ARMD. During early stage, most people don’t re-
alize any of the symptoms. Therefore, it is crucial to have regular 
eye exams. Early ARMD is diagnosed by the appearance of drusen 
the size of 63 microns by the macula. In the intermediate ARMD, 
there may be some vison blur in the central vision and by late 
ARMD there is a noticeable vision loss in the central vision.
Medical experts aren’t exactly sure what causes ARMD but 
once present, many factors contribute to its progression. A per-
son’s age is by far the biggest factor for ARMD. Once one turns 50, 
they should visit an optometrist for a comprehensive dilated eye 
exam. Many eye diseases that don’t have any warning signs can be 
detected with such an eye exam. This exam includes a visual acuity 
test, a visual field test, dilation, and tonometry. Annual exams are 
recommended once a year once one turns 60. However, if one 
is African American, then they should get one when they turn 40 
since they have a higher risk for glaucoma. Although there aren’t 
any cures presently available, there are numerous treatments t for 
ARMD. Many doctors may prescribe a strict diet and exercise to 
slow down the progression. However, none of them can cure the 
disease, except potentially stem cells. 
Although stem cells may offer new therapies, their use has 
been very controversial. People oppose stem cell research since 
one is harvesting a fertilized egg. They believe that this is wrong 
since this is tantamount to killing an unborn child, and therefore 
one should respect the value of a human life. However, others 
feel that morally it’s our duty to prevent or alleviate a person 
from suffering. 
Methods
Literature for this article was obtained primarily using Touro 
College’s Online library. Other databases, such as PubMed, were 
used. Additionally, Google Scholar was valuable for finding nec-
essary and relevant articles.
Discussion
The retina of the eye is tasked with converting light into vision. At 
the center of the retina is the macula. In the retina, there are the 
rods and cones which process light into nerve impulses. Behind 
the photoreceptor layer is the retinal pigmented epithelium (RPE). 
The RPE is tasked with delivering nutrients and removing wastes 
from the photoreceptor cells. In ARMD, RPE stops functioning, 
causing the cones and rods to deteriorate. Today, scientists are 
using stem cell research to understand how diverse cells in the 
retina interact with one another. This has led to discovering new 
ways of replacing photoreceptors and the underlying RPE.
Generally, replacing dead cells with stem cells is very challeng-
ing since the stem cells would have to establish new connections 
with the surrounding nerve fibers that ultimately relay the mes-
sage to the brain. However, the eye is a great target for stem cell 
research since there are many barriers in the eye, such as tight 
cell junctions, therefore making it relatively self-contained. This 
prevents the migration of cells outside of the eye. Furthermore, 
with the use of an ophthalmoscope it is easy to assess the ef-
fectiveness of the treatments. Doctors can also compare the 
treated eye with the other eye to evaluate the effectiveness of 
the treatments.
RPE cells are easier to integrate with existing retinal cells since 
they don’t need to connect with nerve fibers. With stem cells 
research, one can use new RPE cells to replace dead RPE cells. 
If the stem cells are replaced before the photoreceptors have 
completely deteriorated, then the new RPE cells may be able to 
prevent existing photoreceptors from dying, thereby preventing 
the progression of the disease. Stem cells can also be used to 
discover new therapies. When damaged RPE cells are stressed, 
they produce characteristics of ARMD. These damaged cells can 
then be studied to evaluate the different surface markers pres-
ent which can help in early intervention and in getting a better 
diagnosis.
Scientists have come up with different methods to replace the 
RPE layer. One method is using human embryonic stem cells. 
These cells are naturally pluripotent when harvested and can 
renew for long periods if properly maintained in vitro. They can 
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transform into the ectoderm, endoderm, and mesoderm. These 
three primary germ layers can differentiate into all the cells in 
the body. However, there are numerous obstacles raised with 
this method. One of the problems is whether it is ethical to 
harvest embryos since they can turn into a fetus (Narsinh, et. al., 
2011). Another challenge that must be overcome is the limited 
supply of human embryo donors.
Another method researchers have used is induced pluripo-
tent stem cells 
(hiPSCs). These are usually epithelial cells that are reprogramed 
to behave like embryonic stem cells. They can then be used to 
grow rods and cones or RPE cells. The landmark discovery of 
hiPSCs has been hailed as a significant advance in stem cell re-
search. This method circumvents the ethical debate with embry-
onic stem cells since no human embryo is destroyed ex utero. 
However, there are numerous problems with this method as well. 
Extensive research has shown that these cultures cells can turn 
into benign or malignant tumors (Ho, et. al., 2012). Therefore, 
these issues preclude clinical use of these cells for now.
Another method which scientists are experimenting with is 
adult stem cells. This method entails growing RPE specific stem 
cells from adult stem cells. One source for such cells is from 
eyes donated to eye banks. These cells are less likely to be re-
jected if used in implants. However, there usually is a limited 
amount in each tissue, therefore making it harder to find and 
purify. Furthermore, these cells can’t be stored for any length of 
time before they turn cancerous (Reya, et. al., 2001). 
Delivery Method for Stem Cells
Although there are no FDA approved cures for ARMD, implanta-
tion of healthy RPE into the macula may prove to be an effective 
treatment. The following procedure was used to deliver RPE into 
rats. After the rat was put under a general anesthetic, a hole was 
created in the eye using a sharp needle. Then, a blunt needle was 
inserted into the hole until it reached the RPE layer, into which 
the stem cells were injected (Westenskow, et. al., 2015). 
In one study, animal models, such as rats and mice with 
macular degeneration, were treated with stem cells that be-
come RPE cells (Lu, et. al., 2009). To simulate real life condi-
tions, the rats were under a 12-hour light /dark cycle. One 
day prior to their transplantation, all animals in the main ex-
periment were administered cyclosporine to prevent organ 
rejection. Before the researchers administered the cells, they 
washed the cells in balance salt solution. Two weeks after the 
transplantation, the rats received an intraperitoneal injection 
of dexamethasone. This steroid was injected to treat the re-
sulting inflammation. 
These injected cells sustained visual function and photore-
ceptor integrity without any cancerous cell formation. Visual 
acuity increased when the models received a dose between 
5000-100,000 RPE cells. Following the procedure, the rats were 
monitored to check for any adverse reaction. They found that 
visual function was sustained for at least two months. The cells 
themselves survived for at least half a year before they started 
to deteriorate. However, this deterioration in visual acuity can 
be due to insufficient cyclosporine. Another hypothesis of why 
the cells deteriorated can be because the transplantation may 
need to be repeated several times in order to sustain their ther-
apeutic effect.
ARMD Treatments
For early dry ARMD, doctors recommend a diet that is high 
in antioxidants, such as strawberries and oranges. However, if 
the patient has an advanced stage of dry ARMD, such as GA, 
then the doctor may prescribe supplements that increase vital 
vitamins that support the cell.
Until recently, the only treatment for wet ARMD was laser 
photocoagulation. This treatment by an ophthalmologist is a 
minimally invasive procedure which uses a laser to burn and 
destroy leaking blood vessels. However, this treatment cannot 
restore vision that has been lost already. One drawback to 
their use is that most CNV lesions are too big to be treated 
by laser coagulation. Another is that there is a high chance that 
the leakage will reoccur over time. Because of these limitations, 
scientists have been looking for alternative therapies that are 
safe and effective for a long period of time.
One alternative treatment that is widely used today is Anti-
vascular endothelial growth factor (VEGF) therapy. This thera-
py includes periodic intraocular injections of a chemical called 
anti-VEGF. Normally, VEGF is beneficial for the circulatory sys-
tem since it helps promote the growth of new blood vessels. 
However, having too much by the macula can have deleterious 
effects on it since they promote the growth of weak new blood 
vessels. This intravitreal shot of anti VEGF stops the develop-
ment of new blood vessels by the macula, thereby preventing 
any further leaks. However, there are numerous side effects 
with this treatment. Patients have complained about vitreous 
floaters. This happens since the doctor punctures the vitreous 
layer of the eye. Another side effect observed was an elevated 
eye pressure. This can cause glaucoma if left untreated.
Human Implant
Although stem cells have been proposed as a potential treat-
ment in treating ARMD, there are still numerous drawbacks to 
their use. Safety concerns have been raised since there is a risk 
that these cells may turn into unwanted cell types which can lead 
to tumor formation in the eye and potential immune rejection. 
Although stem cells were discovered in the late 1990s, scientists 
did not know how to find a safe way of implanting them. The 
first reported transplanted hESC-derived cells into the macula 
was in 2012. hESC-derived retinal pigment epithelium cells were 
transplanted into the subretinal portion of the of the eyes of 
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dry ARMD patients (Schwartz, et. al., 2012). Ninety-nine percent 
of the stem cells differentiated into RPE cells. These differenti-
ated cells integrated into the host forming a homogenous RPE 
layer. Post-surgery, structural evidence showed that the cells had 
attached and continued to persist during the study. During the 
first four months, there were no signs of hyperproliferation, cell 
rejection, or abnormal growth. 
The scientists didn’t find any signs of adverse proliferation or 
any other type of ocular disease. This method proved to be a 
safer method for treating ARMD than other conventional meth-
ods, such as vitreoretinal surgery and immunosuppression. The 
results of this study provide the first evidence for medium to 
long term safety as well as graft efficacy. These results suggest that 
stem cells can be a safe alternative for many medical diseases that 
require tissue replacement. Therapeutic goals for the future will 
be to treat the patient in the earlier stages of macular degenera-
tion, thereby preventing the photoreceptors from decaying.
Risk Factor
A study was conducted to evaluate the effects of antioxidants 
on AMRD. In this clinical experiment, they enrolled 3,640 partici-
pants who showed signs of ARMD. These participants had drusen 
buildup in at least one of their retinas. The size of drusen build-
up was between 63-150 microns. Participants were randomly 
assigned supplements that contained either 500 mg L-ascorbic 
acid, 400 IU tocopherols, or a placebo. The researchers found 
that compared to the placebo a high dose of L-ascorbic acid 
and various tocopherols may delay the progression of ARMD 
and other forms of vision loss. These supplements showed no 
adverse effects, proving their safety (Age-Related Eye Disease 
Study Research Group, 2001).
A study was conducted to assess the risk of smoking in men. 
This study consisted of 21,157 US male physicians who did not 
have any known diagnosis of ARMD. Of them, 11% were current 
smokers, 39% were past smokers, and 50% that never smoked. 
Over the course of 12 years, they found 268 incidents of ARMD. 
Current smokers who smoked a pack a day had a 240 percent 
risk increase compared to nonsmokers. Past smokers had a 30 
percent increased risk of contracting ARMD. Current smokers 
who smoke less than 20 cigarettes had only a modest risk in-
crease of 26 percent (Christen, et. al., 1996). Unlike other risk 
factors, such as age, smoking is an avoidable risk factor.
Since there aren’t any cures that are reliable for ARMD, it is 
therefore recommended to avoid smoking altogether. However, 
it could be that the study on smoking isn’t 100 percent accurate. 
It could be that the subjects who didn’t smoke had a slower 
progression since they ate foods rich in omega-3 fatty acid. This 
acid can be found in many common household products, such 
as fish and canola oil. In a study conducted with 681 twins, they 
found that having 2 or more servings of fish reduced the risk of 
ARMD by 45 percent (Seddon, et. al., 2006).
Although some fruits and vegetables can slow down the pro-
gression of ARMD, such as those rich in L-ascorbic acid and 
tocopherols, other vegetables can be bad for ARMD. One study 
tried to find out if dietary nitrates can increase your chance 
of getting ARMD. These nitrates can be found in leafy vegeta-
bles, such as lettuce and spinach. In this study, there were 2,856 
participants. The scientists took numerous potential cofounders 
into account such as age, sex, smoking, energy intake, and fish 
consumption. The participants were monitored for 15 years. 
The scientists found that those who had a dietary nitrate intake 
had a 39 percent increase incidence of having ARMD (Gopinath, 
et. al., 2018). However, this percentage increase cannot be said 
to apply for all ethnic groups.
A prospective cohort study of 6,176 participants between 
the ages of 45 to 85 was used to find the prevalence of ARMD 
between four racial groups. These groups were white, black, 
Hispanic, and Chinese. The method they used to test for ARMD 
was by taking a picture of the fundus through the dark-adapted 
pupils, whereupon they were able to measure the drusen size. 
What they found is that Hispanics had a 1.8 percent increase 
in prevalence compared to the black ethnic group. The Chinese 
had a 2.2 percent increase, and the white had a 3 percent in-
crease compared to the blacks. Differences in age, gender, 
pupil size, body mass index, smoking, alcohol drinking history, 
diabetes, and hypertension status did not explain the variability 
among the 4 racial/ethnic groups (Klein, et. al., 2006).
A person’s age is by far the biggest factor for ARMD. In a 
population-based study, scientists tried to find the prevalence 
of ARMD in a sample of Hispanic individuals over the age of 
50. All 4,774 participants had an initial ophthalmic evaluation to 
determine a baseline for comparison. Over the course of the 
study, the scientists monitored drusen size, drusen type, and 
the area covered by drusen. They found that the prevalence of 
early and late ARMD increased with age. The prevalence of early 
ARMD varied with age as follows: people between 50 and 60 
had a 20 percent increase, while those aged 80 and older had a 
54 percent increase. The prevalence of late ARMD varied with 
age as well. Those in the age group of 50 to 60 had a .1 percent 
increase, while those 80 years and older had a 4.3 percent in-
crease (Muñoz, et. al., 2005). 
Conclusion
Currently, there is no FDA approved cure for ARMD. However, 
one promising cure currently being researched is stem cell 
transplantation. However, there are numerous obstacles that 
still need to be overcome before they can be safely implanted 
into patients. Depending on the type of ARMD, doctors may ei-
ther recommend leading a healthier lifestyle or that one should 
undergo surgery. As one ages, one is more prone to getting 
ARMD. Therefore, it is important to get a comprehensive dilated 
eye exam periodically.
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